Nasal DNA Vaccine Protects Against Tuberculosis
Researchers have developed an experimental therapeutic nasal DNA vaccine for tuberculosis.
New HIV Vaccine Could Protect Against Development of HIV Infection and AIDS
Scientists have developed a new HIV vaccine that has the potential to protect humans from developing HIV infection and AIDS.
BCG Vaccine Linked to Changes in Brain Immunity and Alzheimer’s Biomarkers
The Bacillus Calmette-Guérin accine may alter immune activity around the brain and change levels of a protein closely associated with Alzheimer’s disease in older adults without evidence of the condition.
FDA Approves Veligrotug-vvze (Lumvoa) for Thyroid Eye Disease
The U.S. Food and Drug Administration has approved veligrotug-vvze (Lumvoa; Viridian Therapeutics) to treat thyroid eye disease.
Shingles Vaccine Reduces Risk of a Dementia Diagnosis
According to a cohort study using target trial emulation, older adults at higher risk for dementia are less likely to have a dementia diagnosis if they received a herpes zoster (shingles) vaccine.
IVIG Reduces Grade 2 Infections by 67 Percent in CLL
A study has found that intravenous immune globulin (IVIG) reduces grade 2 infections by 67 percent in patients with chronic lymphocytic leukemia.
High-Dose Flu Vaccine Significantly Lowers Risk of Developing Alzheimer’s
Researchers have found that adults 65 and older who received a high-dose influenza vaccine had a significantly lower risk of developing Alzheimer’s disease compared to those who received the standard dose.
IVIG Effective in Treating Infants with HDFN
A recent study has found intravenous immune globulin (IVIG) therapy in infants with hemolytic disease of the fetus and newborn (HDFN) found that it could be beneficial.
IVIG Plus IVMP Does Not Increase Remission Rates in CIDP Patients
According to a recent study, adding intravenous methylprednisolone to intravenous immune globulin induction therapy does not significantly increase remission rates among patients with chronic inflammatory demyelinating polyradiculoneuropathy.
FDA Grants Breakthrough Designation for Wayrilz to Treat Autoimmune Hemolytic Anemia
The U.S. Food and Drug Administration has granted a designation as breakthrough therapy to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase inhibitor, for the treatment of patients with warm autoimmune hemolytic anemia.